However, even for the most promising candidate targets, including GlialCAM and AN02, antibody responses are only detected in 15% to 25% of MS patients (20, 24), suggesting that there is not a universal or even prevalent mimicry mechanism likely to be operative. Here, HEPACAM is linked to myeloid sarcoma.